Literature DB >> 33001186

Clinical Application of Multiple Reaction Monitoring-Mass Spectrometry to Human Epidermal Growth Factor Receptor 2 Measurements as a Potential Diagnostic Tool for Breast Cancer Therapy.

Misol Do1, Hyunsoo Kim2, Injoon Yeo2, Jihyeon Lee1, In Ae Park3, Han Suk Ryu3, Youngsoo Kim1,2.   

Abstract

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is often overexpressed in breast cancer and correlates with a worse prognosis. Thus, the accurate detection of HER2 is crucial for providing the appropriate measures for patients. However, the current techniques used to detect HER2 status, immunohistochemistry and fluorescence in situ hybridization (FISH), have limitations. Specifically, FISH, which is mandatory for arbitrating 2+ cases, is time-consuming and costly. To address this shortcoming, we established a multiple reaction monitoring-mass spectrometry (MRM-MS) assay that improves on existing methods for differentiating HER2 status.
METHODS: We quantified HER2 expression levels in 210 breast cancer formalin-fixed paraffin-embedded (FFPE) tissue samples by MRM-MS. We aimed to improve the accuracy and precision of HER2 quantification by simplifying the sample preparation through predicting the number of FFPE slides required to ensure an adequate amount of protein and using the expression levels of an epithelial cell-specific protein as a normalization factor when measuring HER2 expression levels.
RESULTS: To assess the correlation between MRM-MS and IHC/FISH data, HER2 quantitative data from MRM-MS were divided by the expression levels of junctional adhesion molecule A, an epithelial cell-specific protein, prior to statistical analysis. The normalized HER2 amounts distinguished between HER2 2+/FISH-negative and 2+/FISH-positive groups (AUROC = 0.908), which could not be differentiated by IHC. In addition, all HER2 status were discriminated by MRM-MS.
CONCLUSIONS: This MRM-MS assay yields more accurate HER2 expression levels relative to immunohistochemistry and should help to guide clinicians toward the proper treatment for breast cancer patients, based on their HER2 expression. © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  breast cancer; formalin-fixed paraffin-embedded (FFPE); human epidermal growth factor receptor 2 (HER2); multiple reaction monitoring-mass spectrometry (MRM-MS); targeted proteomics

Mesh:

Substances:

Year:  2020        PMID: 33001186     DOI: 10.1093/clinchem/hvaa178

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.

Authors:  Jeffrey R Whiteaker; Rachel A Lundeen; Lei Zhao; Regine M Schoenherr; Aura Burian; Dongqing Huang; Ulianna Voytovich; Tao Wang; Jacob J Kennedy; Richard G Ivey; Chenwei Lin; Oscar D Murillo; Travis D Lorentzen; Mathangi Thiagarajan; Simona Colantonio; Tessa W Caceres; Rhonda R Roberts; Joseph G Knotts; Joshua J Reading; Jan A Kaczmarczyk; Christopher W Richardson; Sandra S Garcia-Buntley; William Bocik; Stephen M Hewitt; Karen E Murray; Nhan Do; Mary Brophy; Stephen W Wilz; Hongbo Yu; Samuel Ajjarapu; Emily Boja; Tara Hiltke; Henry Rodriguez; Amanda G Paulovich
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 8.786

2.  The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies.

Authors:  Steve Sweet; David Chain; Wen Yu; Philip Martin; Marlon Rebelatto; Andrew Chambers; Fabiola Cecchi; Yeoun Jin Kim
Journal:  Sci Rep       Date:  2022-08-16       Impact factor: 4.996

3.  Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Laura C Kennedy; Dustin E Bosch; Melissa L Lerch; Regine M Schoenherr; Lei Zhao; ChenWei Lin; Shrabanti Chowdhury; Mark R Kilgore; Kimberly H Allison; Pei Wang; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  Clin Chem       Date:  2021-07-06       Impact factor: 12.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.